Company intelligence / Profile preview
Reforgene Medicine
Guangzhou, Guangdong, Chinareforgene.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Reforgene Medicine’s lead candidate, RM 001, a genetically modified autologous cell-based gene-editing therapy for beta-thalassaemia, has demonstrated a 100% cure rate in Phase I clinical trials. Pooled efficacy and safety data from phase 0 and phase I/II trials have been presented at major hematology conferences through late 2024. The company is also advancing preclinical programs targeting other genetic diseases.
- Therapeutic areas
- Rare DiseasesNeurologyOphthalmologyHematologyOncologyOther
- Modalities
- Gene therapyCell therapyHaematopoietic stem cell therapyGenetically modified autologous cell based therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Reforgene Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reforgene Medicine.